CareDx (CDNA) Q2 2026: Revenue Soars 52% as NavDx and Transplant Volumes Expand Core Platform
CareDx’s transformation into a focused precision diagnostics leader is now delivering scale, with revenue up sharply and specialty oncology integration underway. The company’s strategic pivot to core molecular testing, highlighted by the NavDx acquisition and robust transplant volume growth, is expanding its total addressable market and margin structure. Forward execution now hinges on operationalizing specialty oncology, scaling new launches, and sustaining margin discipline as reimbursement and integration milestones approach.
Summary
- Transplant and Oncology Integration Advances: NavDx acquisition and transplant volume gains reinforce CareDx’s core model expansion.
- Margin Structure Strengthens: Gross margin uplift reflects portfolio focus, operational leverage, and divestiture of lower-margin businesses.
- Pipeline and Reimbursement Tailwinds: Publication milestones and finalized Medicare coverage set the stage for further platform adoption.
Business Overview
CareDx is a precision medicine diagnostics company specializing in molecular testing for transplantation, specialty oncology, and cell therapy. Its business model centers on repeat molecular tests that guide clinical decision-making, producing revenue through testing services, patient and digital solutions, and previously, lab products (now divested). The major segments are transplant diagnostics, newly acquired specialty oncology (NavDx), and patient/digital solutions, each contributing to a recurring, evidence-driven revenue stream.
Performance Analysis
CareDx delivered a decisive top-line acceleration, with total revenue up 52% year-over-year to $132 million, fueled by a 61% jump in testing services and a 17% rise in test volumes. The transplant business remains the core revenue engine, but the addition of NavDx in specialty oncology is already driving incremental growth and broadening the company’s addressable market. Non-GAAP gross margins increased to 74%, reflecting both operational discipline and the impact of out-of-period revenue, while adjusted EBITDA improved markedly, underscoring scalable profitability as the business shifts to higher-value segments.
The divestiture of the lab products business, completed at quarter-end, further sharpened the company’s focus and improved working capital dynamics, removing a lower-margin, inventory-heavy operation. Cash flow from operations was robust, and the balance sheet is debt-free with $374 million in cash. Notably, out-of-period revenue provided a near-term boost, but underlying margin trends remain healthy even when excluding these effects.
- Transplant Testing Drives Core Growth: Volume and revenue per test both rose, with workflow improvements and expanded use cases increasing average tests per patient.
- Specialty Oncology Adds Scale: NavDx contributed $24 million in H2 guidance and is expected to grow 30-40% annually as integration and evidence generation progress.
- Margin Expansion from Portfolio Focus: Gross margin uplift reflects the exit from lab products and operational leverage in core testing services.
CareDx’s performance validates the repeatable, evidence-driven model and positions the company for continued profitable growth as new launches and reimbursement tailwinds materialize.
Executive Commentary
"We have transformed CareDx into a differentiated precision molecular diagnostics company with a unique set of core competencies that position us for continued profitable growth. Our performance reflects that our strategy is working and we look forward to building on our momentum as we integrate NavDx and launch into cell therapy."
John Hanna, President and Chief Executive Officer
"We generated cash flow from operations of 31 million this quarter and 94 million over the last four quarters. And we ended the quarter with 374 million in cash and cash equivalents and no debt."
Keith Kennedy, Chief Operating Officer and Chief Financial Officer
Strategic Positioning
1. Core Portfolio Focus and Divestiture Discipline
CareDx has exited non-core businesses and doubled down on its highest-value opportunities, notably transplant and specialty oncology molecular diagnostics. The sale of the lab products business removed a margin drag and freed up resources for core growth initiatives, demonstrating commitment to capital discipline and operational focus.
2. Evidence Generation and Clinical Integration
The company’s model is rooted in generating robust clinical evidence to drive adoption and reimbursement. New data for Alaheim (cell therapy recurrence monitoring) and Histomap Kidney (biopsy enhancement) support differentiation and future coverage. Recent publications and clinical guidelines are accelerating adoption in both transplant and oncology settings.
3. Specialty Oncology Platform Expansion
NavDx, a solid tumor minimal residual disease (MRD) platform, is being integrated with CareDx’s commercial infrastructure, workflow expertise, and revenue cycle management. The company is expanding the dedicated sales team, investing in evidence generation, and targeting higher ASPs as coverage and clinical utility are established.
4. Workflow and Digital Connectivity
CareDx is leveraging digital integration (Epic EMR, care portal) to embed its tests into routine clinical practice, enhancing stickiness and streamlining ordering and results review. With 90% of transplant customers now electronically connected, operational friction is falling and test utilization is rising.
5. Reimbursement and Policy Tailwinds
The finalized Medicare local coverage determination affirms reimbursement for core transplant tests and sets a pathway for future products like Histomap Kidney. This regulatory clarity reduces reimbursement risk and supports broader adoption and innovation in the coming years.
Key Considerations
This quarter marks a strategic inflection, with CareDx now operating as a focused, integrated diagnostics platform across transplant and oncology. The company’s evidence-driven approach, operational leverage, and digital integration create a defensible competitive moat, but execution risks remain as new markets are scaled and integration efforts accelerate.
Key Considerations:
- NavDx Integration Complexity: Moving specialty oncology billing and workflows onto CareDx’s systems is underway, but full operational and margin synergies will take time to realize.
- Margin Sustainability: While gross margins are elevated by out-of-period revenue, underlying margin strength in core testing must persist as volume mix shifts and pricing levers are activated.
- Pipeline Commercialization Timing: Alaheim and Histomap Kidney represent organic expansion opportunities, but success depends on evidence publication, CLIA launch readiness, and reimbursement milestones in 2027.
- Digital Penetration Drives Utilization: The company’s investment in EMR integration and workflow support is increasing average tests per patient and embedding CareDx more deeply into clinical routines.
Risks
Integration of NavDx presents operational and reimbursement risk, especially as billing and claims transition to internal systems. Sustaining high gross margins requires continued payer support, favorable ASP trends, and avoidance of pricing pressure as specialty oncology scales. Pipeline launches and reimbursement coverage for new products remain subject to clinical evidence generation and regulatory review. Any delay or negative outcome in these areas could impact future growth and profitability.
Forward Outlook
For Q3 2026, CareDx guided to:
- Testing volume of 72,600, with 58,000 transplant and 14,600 specialty oncology tests.
- Out-of-period revenue of $8 million.
For full-year 2026, management raised guidance:
- Total revenue of $490 to $500 million (30% YoY growth at the midpoint).
- Adjusted EBITDA of $66 to $78 million (15% margin at midpoint).
Management highlighted several factors that will shape results:
- Specialty oncology volumes expected to grow 30-40% annually, with ASP uplift as coverage and evidence build.
- CLIA readiness and publication milestones for pipeline launches (Alaheim, Histomap Kidney) are targeted by year-end, supporting 2027 commercialization.
Takeaways
CareDx’s transformation is translating into scale, margin expansion, and a stronger competitive position.
- Core Testing Model Validated: Transplant volume growth and deeper clinical integration are driving recurring, defensible revenues as digital and workflow investments pay off.
- Specialty Oncology Adds Growth Optionality: NavDx integration is expanding the platform into new markets, but execution on billing, salesforce expansion, and evidence generation will determine the pace of value realization.
- Margin and Cash Flow Discipline: Portfolio focus and operational leverage are supporting margin uplift and robust cash generation, with further upside as pipeline launches and reimbursement tailwinds emerge.
Conclusion
CareDx’s sharp strategic focus and disciplined execution have positioned it as a leader in precision molecular diagnostics for high-value, repeat testing markets. With specialty oncology integration underway and pipeline launches on the horizon, the company’s evidence-driven model and operational leverage support a constructive outlook, though integration and reimbursement execution remain key watchpoints.
Industry Read-Through
CareDx’s results underscore the rising importance of integrated, evidence-based molecular diagnostics in both transplant and oncology care. The move toward digital workflow integration, clinical guideline adoption, and payer coverage is accelerating the transition from single-use to longitudinal testing models across precision medicine. For diagnostics peers, the quarter highlights the value of focused portfolios, operational discipline, and deep clinical engagement to drive adoption and margin expansion. The successful divestiture of lower-margin businesses and disciplined integration of new platforms offer a playbook for diagnostics companies navigating reimbursement and adoption headwinds in specialized, high-cost disease markets.